05.22.26 -- Gaining An Edge In GLP-1 Production

Discover how custom manifolds enhance allogeneic therapy development from formulation to commercialization by improving process control, scalability, and efficiency.

With each batch of cell and gene therapy product representing a wealth of lifesaving potential, this biopharma company needed the right packaging solution for its relatively new therapy applications.

Life science teams increasingly need tools that scale, simplify workflows, and reduce operational costs. Examine how emerging instrumentation focuses on usability, performance, and manufacturability.

Cell polarity, the asymmetric organization of eukaryotic cells, is vital for tissue development and homeostasis, but intracellular assembly of the protein complexes involved remains unclear.

Middlesex County, NJ, is a hotbed for the life sciences, offering a deep talent pool, an extensive R&D presence, and dedicated backing by local government in the form of strategic investment.

Get access to the tools and expertise needed to support process development for biologic therapies from the clinical trial phase to commercialization.

The session highlights how tailored media solutions, combined with strong scientific understanding and scalable manufacturing practices, can support more efficient bioprocess development.

Explore strategies for scaling MSC manufacturing while mitigating biological and operational risks, as well as how closed-system platforms and optimized workflows accelerate the path to commercial cell therapy.

Efficient mRNA production relies on optimized IVT conditions, where NTPs, enzymes, and critical additives work together. See how the right components strengthen mRNA synthesis at every step.

Find out how proactively designing around plant constraints, using high-capacity resins, and leveraging parallel workstreams resulted in a 50% reduction in processing hours and 25% lower costs.

Review a novel adenovirus production process that offers scalable, single-use equipment-compatible solutions, reducing production time and cross-contamination risks.

Learn how to apply ICH Q2(R2) and Q14 to analytical procedures using QbD principles, ATP definition, and lifecycle management strategies to ensure regulatory alignment and product quality.

Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.

Some membranes attract water ("hydrophilic"), while others repel it ("hydrophobic"). Here, we examine which is best for your application.

Delve into how Organ-on-Chip technology significantly enhances drug development processes and improves the accuracy of clinical translation, leading to more effective and reliable therapeutic outcomes.

By leveraging transposase-mediated technologies together with transposon design to achieve semi-targeted integration, drug developers can more efficient and consistent biotherapeutic protein production.

When choosing between protein expression formats such as transient versus stable pools, considerations include speed, cost, titre, and product quality.